Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
Mikio Kamimura,1 Shigeharu Uchiyama,2 Yukio Nakamura,2,3 Shota Ikegami,2 Keijiro Mukaiyama,2 Hiroyuki Kato2 1Center for Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Japan; 2Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan; 3Dep...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-02-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/short-term-bisphosphonate-treatment-reduces-serum-25oh-vitamin-d3-and--peer-reviewed-article-TCRM |
| _version_ | 1818934709447557120 |
|---|---|
| author | Kamimura M Uchiyama S Nakamura Y Ikegami S Mukaiyama K Kato H |
| author_facet | Kamimura M Uchiyama S Nakamura Y Ikegami S Mukaiyama K Kato H |
| author_sort | Kamimura M |
| collection | DOAJ |
| description | Mikio Kamimura,1 Shigeharu Uchiyama,2 Yukio Nakamura,2,3 Shota Ikegami,2 Keijiro Mukaiyama,2 Hiroyuki Kato2 1Center for Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Japan; 2Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan; 3Department of Orthopedic Surgery, Showa-Inan General Hospital, Komagane, Japan Abstract: This study aimed to clarify the effects of short-term bisphosphonate (BP) administration in Japanese osteoporotic patients retrospectively. Daily minodronate (MIN) at 1 mg/day (MIN group) or weekly risedronate (RIS) at 17.5 mg/week (RIS group) was primarily prescribed for each patient. We analyzed the laboratory data of 35 cases (18 of MIN and 17 of RIS) before the start of treatment and at 4 months afterward. The changes in 25(OH)D3, whole parathyroid hormone (PTH), serum pentosidine, and the bone turnover markers urinary cross-linked N-telopeptide of type I collagen (NTX), serum tartrate-resistant acid phosphatase (TRACP)-5b, bone-specific alkaline phosphatase (BAP), and undercarboxylated osteocalcin were evaluated. Overall, serum 25(OH)D3 was significantly decreased from 21.8 to 18.4 ng/mL at 4 months, with a percent change of –14.7%. Whole PTH increased significantly from 23.4 to 30.0 pg/mL, with a percent change of 32.1%. Serum pentosidine rose from 0.0306 to 0.0337 µg/mL, with a percent change of 15.2%. In group comparisons, 25(OH)D3 and pentosidine showed comparable changes in both groups after 4 months of treatment, whereas whole PTH became significantly more increased in the MIN group. All bone turnover markers were significantly decreased at 4 months in both groups. Compared with the RIS group, the MIN group exhibited significantly larger value changes for urinary NTX, serum TRACP-5b, and BAP at the study end point. This study demonstrated that serum 25(OH)D3 became significantly decreased after only 4 months of BP treatment in Japanese osteoporotic patients and confirmed that MIN more strongly inhibited bone turnover as compared with RIS. Keywords: minodronate, risedronate, 25(OH) vitamin D3, parathyroid hormone, pentosidine |
| first_indexed | 2024-12-20T05:08:35Z |
| format | Article |
| id | doaj.art-3112ead3ff224d06a6e3b927f51c6740 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-20T05:08:35Z |
| publishDate | 2017-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-3112ead3ff224d06a6e3b927f51c67402022-12-21T19:52:18ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2017-02-01Volume 1316116831297Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markersKamimura MUchiyama SNakamura YIkegami SMukaiyama KKato HMikio Kamimura,1 Shigeharu Uchiyama,2 Yukio Nakamura,2,3 Shota Ikegami,2 Keijiro Mukaiyama,2 Hiroyuki Kato2 1Center for Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Japan; 2Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan; 3Department of Orthopedic Surgery, Showa-Inan General Hospital, Komagane, Japan Abstract: This study aimed to clarify the effects of short-term bisphosphonate (BP) administration in Japanese osteoporotic patients retrospectively. Daily minodronate (MIN) at 1 mg/day (MIN group) or weekly risedronate (RIS) at 17.5 mg/week (RIS group) was primarily prescribed for each patient. We analyzed the laboratory data of 35 cases (18 of MIN and 17 of RIS) before the start of treatment and at 4 months afterward. The changes in 25(OH)D3, whole parathyroid hormone (PTH), serum pentosidine, and the bone turnover markers urinary cross-linked N-telopeptide of type I collagen (NTX), serum tartrate-resistant acid phosphatase (TRACP)-5b, bone-specific alkaline phosphatase (BAP), and undercarboxylated osteocalcin were evaluated. Overall, serum 25(OH)D3 was significantly decreased from 21.8 to 18.4 ng/mL at 4 months, with a percent change of –14.7%. Whole PTH increased significantly from 23.4 to 30.0 pg/mL, with a percent change of 32.1%. Serum pentosidine rose from 0.0306 to 0.0337 µg/mL, with a percent change of 15.2%. In group comparisons, 25(OH)D3 and pentosidine showed comparable changes in both groups after 4 months of treatment, whereas whole PTH became significantly more increased in the MIN group. All bone turnover markers were significantly decreased at 4 months in both groups. Compared with the RIS group, the MIN group exhibited significantly larger value changes for urinary NTX, serum TRACP-5b, and BAP at the study end point. This study demonstrated that serum 25(OH)D3 became significantly decreased after only 4 months of BP treatment in Japanese osteoporotic patients and confirmed that MIN more strongly inhibited bone turnover as compared with RIS. Keywords: minodronate, risedronate, 25(OH) vitamin D3, parathyroid hormone, pentosidinehttps://www.dovepress.com/short-term-bisphosphonate-treatment-reduces-serum-25oh-vitamin-d3-and--peer-reviewed-article-TCRMMinodronateRisedronate25(OH) vitamin D3parathyroid hormonepentosidine |
| spellingShingle | Kamimura M Uchiyama S Nakamura Y Ikegami S Mukaiyama K Kato H Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers Therapeutics and Clinical Risk Management Minodronate Risedronate 25(OH) vitamin D3 parathyroid hormone pentosidine |
| title | Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers |
| title_full | Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers |
| title_fullStr | Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers |
| title_full_unstemmed | Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers |
| title_short | Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers |
| title_sort | short term bisphosphonate treatment reduces serum 25 oh vitamin d3 and alters values of parathyroid hormone pentosidine and bone metabolic markers |
| topic | Minodronate Risedronate 25(OH) vitamin D3 parathyroid hormone pentosidine |
| url | https://www.dovepress.com/short-term-bisphosphonate-treatment-reduces-serum-25oh-vitamin-d3-and--peer-reviewed-article-TCRM |
| work_keys_str_mv | AT kamimuram shorttermbisphosphonatetreatmentreducesserum25ohvitamind3andaltersvaluesofparathyroidhormonepentosidineandbonemetabolicmarkers AT uchiyamas shorttermbisphosphonatetreatmentreducesserum25ohvitamind3andaltersvaluesofparathyroidhormonepentosidineandbonemetabolicmarkers AT nakamuray shorttermbisphosphonatetreatmentreducesserum25ohvitamind3andaltersvaluesofparathyroidhormonepentosidineandbonemetabolicmarkers AT ikegamis shorttermbisphosphonatetreatmentreducesserum25ohvitamind3andaltersvaluesofparathyroidhormonepentosidineandbonemetabolicmarkers AT mukaiyamak shorttermbisphosphonatetreatmentreducesserum25ohvitamind3andaltersvaluesofparathyroidhormonepentosidineandbonemetabolicmarkers AT katoh shorttermbisphosphonatetreatmentreducesserum25ohvitamind3andaltersvaluesofparathyroidhormonepentosidineandbonemetabolicmarkers |